Position in ENLV
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$943
+$230 QoQ
Shares Held
1,015
0.0% QoQ
Ownership
0.006%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2022
10 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in ENLV Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Arax Advisory Partners holds $6,272,368 across 181 Biotechnology names. ENLV ranks #111 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | EXEL |
Exelixis, Inc.
|
18,720 | $802,900 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
1,423 | $635,426 | |
| 3 | TECH |
BIO-TECHNE Corp
|
11,543 | $603,237 | |
| 4 | INCY |
Incyte Corp
|
6,007 | $565,378 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
613 | $473,628 | |
| 6 | JAZZ |
Jazz Pharmaceuticals plc
|
2,012 | $380,368 | |
| 7 | MESO |
Mesoblast Ltd
|
24,425 | $375,656 | |
| 8 | CGEN |
Compugen Ltd
|
131,800 | $280,734 |
All Filings in ENLV
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $943 | 1,015 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $713 | 1,015 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $1,055 | 1,015 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $1,136 | 1,015 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $984 | 1,015 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $1,187 | 1,015 | Shares | Sole | 2025-02-05 | |
| 2024-09-30 | $1,033 | 615 | Shares | Sole | 2024-11-06 | |
| 2024-06-30 | $873 | 615 | Shares | Sole | 2024-08-06 | |
| 2023-06-30 | $761 | 290 | Shares | Sole | 2023-08-14 | |
| 2022-06-30 | $632 | 140 | Shares | Sole | 2022-08-22 | |
| No filing history on record for this holder in this stock. | ||||||